SYNTHESIS OF UP TO TEN SAMPLE COMPOUNDS PER YEAR (CONTINUITY FOR 66C)

发展治疗计划/DCTD利用药物获取倡议（DAI）独立获取克数量的所有已知治疗药物，这些药物正在人类临床开发中用于治疗癌症。作为DAI的一部分，药物合成和化学处定期聘请其承包商合成克数量的选定化合物。合成目标1项目旨在合成至少5克的1-（4-（苄基氨基）-5,6,7,8-四氢吡啶[2,3-d]嘧啶-2-基）-2-甲基- 1h -吲哚-4-羧酰胺，编号为CB-5339和NSC831868。

The Developmental Therapeutics Program/DCTD utilizes the Drug Acquisition Initiative (DAI) to independently acquire gram quantities of all known therapeutic agents that are under human clinical development for the treatment of cancer. As part of the DAI the Drug Synthesis and Chemistry Branch periodically engages its contractors to synthesize gram quantities of select compounds. The Synthesis Target 1 Project is directed at the synthesis of a minimum of 5 grams of 1-(4-(benzylamino)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide, designated as CB-5339 and NSC831868.